

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

Date: 14.11.2024

To,  
The Head – Listing & Compliance  
National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,  
Bandra (E) Mumbai – 400 051

**Symbol: AMBEY**  
**ISIN : INE0M3I01029**

**Subject: Submission of Revised Financial Results Due to Typographical Error in the Unaudited Financial Results for the Half-Year Ended September 30, 2024**

Dear Sir/Madam,

This letter is to inform you of a typographical error identified in the Unaudited Financial Results of the Company for the half-year ended September 30, 2024, which was recently uploaded to the National Stock Exchange of India (NSE) on November 13, 2024.

Upon review, we discovered an error in the final version of the Unaudited Financial Results, which led to the incorrect presentation of the Earnings Per Share (EPS) as 0.16 instead of the correct value of 1.38.

This mistake was purely unintentional and occurred due to a typographical oversight. We have now corrected the error, and the revised financial results reflect the accurate EPS value of 1.38.

Ambey Laboratories Limited recognizes the importance of accurate and transparent financial reporting to all stakeholders. We are committed to promptly addressing this issue to maintain the integrity of our financial information. Accordingly, we kindly request your permission to replace the previously uploaded documents with the corrected versions that accurately reflect the correct EPS.

Please find attached the revised set of Unaudited Financial Results for the half-year ended September 30, 2024.

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

We apologize for any inconvenience caused by this error and appreciate your understanding and cooperation in processing this rectification request.

Should you require any further information or clarification, please do not hesitate to contact us at [cs@ambeylab.com](mailto:cs@ambeylab.com).

We look forward to receiving your confirmation of the successful update of our filings on the NSE. Thank you for your time and attention to this matter.

Thanking You,

**For: AMBEY LABORATORIES LIMITED**

**Rimple Sarin**

**Designation: Company Secretary**

**Membership No: A66345**



F.R.N. 022743N

# KAPISH JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987

Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

## Independent Auditor's Review Report on Standalone Unaudited Financial Results for the half year ended 30 September 2024 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Ambey Laboratories Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Ambey Laboratories Limited** ("the Company") for the half year ended 30 September 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. Our responsibility is to express an opinion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. During the half-year ended on 30 September 2024, the Company has issued 62,58,000 equity shares of ₹ 10 each at premium of ₹ 58 by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on 11 July 2024. Accordingly, these Unaudited Financial Results for the half year ended on 30 September 2024 are drawn up in accordance with the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.



5. The Company has utilized proceeds from IPO as per the object clause of the prospectus dated 09 July 2024. Public issue expenses have been debited to the securities premium account and Net IPO proceeds which were un-utilized as at 30 September 2024 were temporarily invested in fixed deposit. Detailed information are given below:

₹ in Lakhs

Sl No.	Object of the Issue	Amount allotted for the object	Amount utilized till 30 Sept 2024	Amount un-utilized till 30 Sept 2024
1	General corporate purpose	912.24	544.05	368.19
2	Public issue expenses	250.00	250.00	-
3	Working capital requirement	3,093.20	3093.20	-
<b>Total</b>		<b>4,255.44</b>	<b>3887.25</b>	<b>368.19</b>

6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the generally accepted accounting principles in India ("GAAP") and in compliance with the applicable Accounting Standard as specified under section 133 of the Companies Act, 2013 as amended,, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **KAPISH JAIN & ASSOCIATES**

Chartered Accountants

Firm Registration No. 022743N



**CA Kapish Jain**

Partner

M. No.: 514162

UDIN: 24514162BKBIAE9845

Place: New Delhi

Date: 13 November 2024

**Ambey Laboratories Limited**

Regd. Office : Ground Floor, Property No.555 Tara Mohalla, Ghitorni, South West Delhi, Delhi, India, 110030

Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002

CIN: U74899DL1985PLC020490, Email:cs@ambeylab.com

**STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS  
FOR THE HALF YEAR ENDED 30 SEPTEMBER 2024**

Sl.No	Particulars	Rs. In Lakhs			
		Half year ended		Year ended	
		30.09.2024 (Unaudited)	31.03.2024 (Audited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	<b>Income</b>				
	a) Revenue from operations	6,765.23	5,997.02	6,050.13	12,047.14
	b) Other income	77.45	155.89	2.64	158.53
	<b>Total income</b>	<b>6,842.68</b>	<b>6,152.91</b>	<b>6,052.77</b>	<b>12,205.67</b>
2	<b>Expenses</b>				
	a) Cost of material consumed	6,118.84	5,743.15	5,432.67	11,175.82
	b) Changes in inventories of work-in-progress, finished goods	(191.51)	(424.16)	(86.55)	(510.71)
	c) Employee benefits expense	72.45	84.57	86.16	170.73
	d) Finance costs	176.50	140.16	101.26	241.42
	e) Depreciation and amortisation expense	120.04	130.61	120.91	251.52
	f) Other expenses	183.17	189.79	114.30	304.09
	<b>Total expenses</b>	<b>6,481.49</b>	<b>5,864.12</b>	<b>5,768.75</b>	<b>11,632.87</b>
3	<b>Profit/(loss) before exceptional item &amp; tax (1-2)</b>	<b>361.19</b>	<b>288.79</b>	<b>284.02</b>	<b>572.80</b>
4	Exceptional Items	-	29.66	-	29.66
5	<b>Profit/(loss) before tax (3-4)</b>	<b>361.19</b>	<b>259.13</b>	<b>284.02</b>	<b>543.16</b>
6	Tax expense	56.27	44.12	46.54	90.68
	Deferred tax charge/ (benefit)	64.63	84.56	(313.58)	(229.02)
	MAT credit entitlement	(56.27)	(44.12)	(46.54)	(90.68)
	<b>Tax expense</b>	<b>64.63</b>	<b>84.56</b>	<b>(313.58)</b>	<b>(229.02)</b>
7	<b>Net Profit/(Loss) after tax (5-6)</b>	<b>296.56</b>	<b>174.58</b>	<b>597.60</b>	<b>772.16</b>
8	<b>Paid-up Equity Share Capital (Face value of Rs.10/- each)</b>	<b>2,494.68</b>	<b>1,868.88</b>	<b>1,774.94</b>	<b>1,868.88</b>
9	Reserves (excluding revaluation reserve)				232.44
10	<b>Earnings per equity share</b> [Nominal value per share Rs. 10] (not annualised, except year end)				
	Basic earnings per share (in ₹)	1.38	0.96	3.37	4.25
	Diluted earnings per share (in ₹)	1.38	0.96	3.37	4.25

**Notes:-**

- The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 13 November 2024.
- The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.
- During the half-year ended on 30 September 2024, the Company has issued 62,58,000 equity shares of ₹ 10 each at premium of Rs. 58 by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on 11th July 2024. Accordingly, these Unaudited Financial Results for the half year ended on 30 September 2024 are drawn up for in accordance with the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The Company has utilised proceeds from IPO as per the object clause of the prospectus dated 09 July 2024 as detailed below:

Sl No.	Object of the Issue	Amount allotted for the object	Amount utilized till 30 Sep 2024	Amount un-utilized till 30 September 2024	Rs. In Lakhs
					Deviation (if any)
1	General corporate purpose	912.24	544.05	368.19	-
2	Public issue expenses*	250.00	250.00	-	-
3	Working capital requirement	3,093.20	3,093.20	-	-
<b>Total</b>		<b>4,255.44</b>	<b>3,887.25</b>	<b>368.19</b>	<b>-</b>

\* Public issue expenses have been debited to the securities premium account

Net IPO proceeds which were un-utilized as at 30 September 2024 were temporarily invested in fixed deposit.

- The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

For and Behalf of Board of  
Ambey Laboratories Limited

  
Sarina Gupta

Director  
DIN 08787098

Date: 13 November 2024  
Place: Gurugram



STANDALONE STATEMENT OF ASSETS & LIABILITIES		Rs. In Lakhs	
		As at 30.09.2024	As at 31.03.2024
<b>Particulars</b>			
<b>EQUITY AND LIABILITIES</b>			
1	<b>Shareholders' funds</b>		
	a) Share capital		
	b) Reserves and surplus	2,494.68	1,868.88
	<b>Total Equity</b>	<b>4,959.64</b>	<b>1,292.44</b>
		<b>7,453.32</b>	<b>3,151.32</b>
2	<b>Share Application Money Pending Allotment</b>		
		-	-
3	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	a) Long-Term Borrowings		
	b) Deferred tax liabilities	1,382.84	1,632.22
	c) Other long-term liabilities	-	-
	d) Long-term provisions	-	-
	<b>Total non-current liabilities</b>	<b>67.60</b>	<b>53.23</b>
	<b>Current liabilities</b>	<b>1,450.44</b>	<b>1,685.45</b>
	a) Short-Term Borrowings		
	b) Trade payables	1,416.39	1,332.21
	(i) Total outstanding dues of micro enterprises and small enterprises;		
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	6.76	3.77
	c) Other current liabilities	2,665.56	1,476.80
	d) Short-term provisions	347.38	177.95
	<b>Total current liabilities</b>	<b>132.87</b>	<b>113.85</b>
	<b>Total equity and liabilities</b>	<b>4,669.96</b>	<b>3,104.38</b>
	<b>Assets</b>	<b>13,473.72</b>	<b>7,941.15</b>
1	<b>Non-current assets</b>		
	a) Property, plant and equipment		
	(i) Property, plant and equipment		
	(ii) Intangible assets	2,374.95	2,321.65
	(iii) Capital work-in-progress	66.80	75.89
	b) Deferred tax assets (Net)	717.51	383.66
	c) Long-term loans and advances	202.98	267.62
	d) Other non-current assets	472.94	50.04
	<b>Total non-current assets</b>	<b>-</b>	<b>-</b>
2	<b>Current assets</b>	<b>3,835.18</b>	<b>3,098.86</b>
	a) Current investment		
	b) Inventories	78.12	78.12
	c) Trade receivables	2,707.36	2,057.46
	d) Cash and bank balances	5,444.25	1,868.83
	e) Short-term loans and advances	417.09	38.03
	f) Other current assets	456.53	363.33
	<b>Total current assets</b>	<b>535.19</b>	<b>436.52</b>
	<b>Total assets</b>	<b>9,638.54</b>	<b>4,842.29</b>
		<b>13,473.72</b>	<b>7,941.15</b>

For and Behalf of Board of  
Ambey Laboratories Limited

  
Sarina Gupta  
Director  
DIN 08787098

Date: 13 November 2024  
Place: Gurugram

STANDALONE STATEMENT OF CASH FLOWS		Rs. In Lakhs	
		For the half year ended	
		As at 30.09.2024	As at 30.09.2023
<b>A.</b>	<b>Cash flow from operating activities</b>		
	Profit/(loss) before tax	361.19	284.02
	Adjustments for :		
	Depreciation and amortisation expense	120.04	120.91
	Net (profit)/ loss on disposal of property, plant and equipment	(1.22)	-
	Interest expense and finance cost	178.50	101.26
	Interest income	(12.59)	(0.03)
	Unrealised foreign currency (gain)/loss	(0.61)	-
		<b>645.31</b>	<b>506.16</b>
	<b>Changes in assets and liabilities</b>		
	(Increase) / Decrease in inventories	(649.89)	294.79
	(Increase) / Decrease in trade receivables	(3,574.81)	(2,180.10)
	(Increase) / Decrease in long term loans and advances	(422.90)	(2.70)
	(Increase) / Decrease in short term loans and advances	(93.20)	(36.97)
	(Increase) / Decrease in other assets	(98.67)	14.11
	Increase / (decrease) in trade payables	1,192.96	1,123.74
	Increase / (decrease) in short term provisions	52.41	-
	Increase / (decrease) in long term provisions	14.37	-
	Increase / (decrease) in other liabilities	169.43	290.23
	<b>Cash generated from operating activities</b>	<b>(2,764.99)</b>	<b>19.26</b>
	Taxes paid (net of refunds)	(33.39)	(85.83)
	<b>Net cash generated from operating activities</b>	<b>(2,798.38)</b>	<b>(66.57)</b>
<b>B.</b>	<b>Cash Flow from Investing Activities</b>		
	(Purchase) Sale of Fixed Assets	(496.89)	(43.31)
	Interest received	12.59	0.03
	Investment in Fixed Deposit	(368.84)	-
	(Purchase) Sale of Current Investment	-	(18.18)
	<b>Net cash generated from/(used in) investing activities</b>	<b>(853.14)</b>	<b>(61.47)</b>
<b>C.</b>	<b>Cash flows from financing activities</b>		
	Interest & Finance Cost	(178.50)	(101.26)
	Proceeds from issues of equity shares	4,005.44	-
	( Repayments ) / proceeds of long term borrowings	(249.38)	140.74
	( Repayments ) / proceeds of short term borrowings	84.18	54.21
	<b>Net cash generated from/(used in) financing activities</b>	<b>3,661.74</b>	<b>93.70</b>
	<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>10.22</b>	<b>(34.33)</b>
	Cash and cash equivalents at the beginning of year	36.50	39.81
	<b>Cash and cash equivalents at the end of year</b>	<b>46.72</b>	<b>5.48</b>

\* The above statement of cash flow has been prepared under the 'Indirect Method'.

For and Behalf of Board of  
Ampey Laboratories Limited.

  
Sarina Gupta  
Director  
DIN 08787098

Date: 13 November 2024  
Place: Gurugram